deltatrials
Recruiting PHASE2 INTERVENTIONAL 2-arm NCT07183748

Psilocybin Microdosing With Psychotherapy for Treatment-Resistant Depression

A Double-blind, Phase II Feasibility Study to Assess the Safety and Efficacy of Psilocybin Microdosing Combined With Psychotherapy in Treatment-resistant Depression

Sponsor: Beersheva Mental Health Center

Conditions Treatment Resistant Depression
Interventions Placebo Psilocybin (drug)
Updated 2 times since 2025 Last updated: Nov 16, 2025 Started: Dec 1, 2025 Primary completion: Jun 1, 2027 Completion: Jun 1, 2028
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT07183748, this PHASE2 trial focuses on Treatment Resistant Depression and remains actively recruiting participants. Sponsored by Beersheva Mental Health Center, it has been updated 2 times since 2025, reflecting limited change activity. Mental health research at this phase helps define safety and dosing parameters for future study.

Status Flow

~Oct 2025 – ~Dec 2025 · 2 months · monthly snapshotRecruiting~Dec 2025 – present · 7 months · monthly snapshotRecruiting

Change History

2 versions recorded

  1. Dec 2025 — Present [monthly]

    Recruiting PHASE2

  2. Oct 2025 — Dec 2025 [monthly]

    Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Beersheva Mental Health Center
  • MSICS PHARMA LTD
Data source: Beersheva Mental Health Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations